Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
Trial details
- Registry ID
- NCT02501018
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as CD34+ cells
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)NCT02501018 | LSTA | Phase 2 | Completed | 2022-05-19Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |